Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52

XTalks

DECEMBER 13, 2023

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff.

RNA 52

RNA Pharma Companies Antibody Life Science 52

Delveinsight

DECEMBER 15, 2020

Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development in the NASH landscape and help its commercialization in the market.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

pharmaphorum

OCTOBER 28, 2020

That narrative, for many patients, is that pharma companies just don’t care”. Pharma is swimming against the tide and can’t pretend that the democratisation of medicines data doesn’t exist — because it’s already here. 72% do not feel listened to by pharmaceutical companies. Yet it is widely mistrusted.

Medicine 117

Medicine Pharma Companies Vaccination Vaccine 117

Drug Discovery World

MAY 6, 2024

As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones.

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

OCTOBER 15, 2021

The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctors 105

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

pharmaphorum

SEPTEMBER 7, 2022

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. But our drug development processes are not perfect. The same is true for Asian and Hispanic populations.

Clinical Trials 90

Clinical Trials Clinical Trials Trials Genetics 90

Drug Discovery World

NOVEMBER 15, 2022

If a pharmaceutical company is racing to identify a new vaccine, for instance, then waiting for three weeks to receive DNA sequences each time can slow down the development process compared to competitors who might have faster timelines.” . The longer the DNA gets, the longer it will take for labs to receive it,” notes Dr Daniels. “If

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

pharmaphorum

SEPTEMBER 1, 2020

The 2010s have seen the development of innovative new classes of medicines, building on the greater understanding of the body since the genome was first sequenced at the end of the last century. New challenges in an age of innovation.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

Drug Discovery World

OCTOBER 4, 2022

This year, genome engineering company Synthego launched a portfolio of Engineered Cell Librariesnto help improve access to CRISPR-edited cells for direct use in functional screening assays. This year has seen some major deals announced by big pharma companies.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

DECEMBER 15, 2022

With the bell then tolling within the House of Commons, Brine concluded that prevention and care were critical, and particularly future cancer care – getting ‘upstream’ of symptom-led early diagnosis with genomic medicine, despite the ‘billion ethical questions’ that go alongside that. An extraordinary feat of logistics, he called it.

Life Science 83

Life Science Medicine Clinical Trials Clinical Trials 83

pharmaphorum

MARCH 30, 2021

Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this is an immensely challenging area to operate in, the company’s senior vice president of its international business, Camilla Harder Hartvig, says it provides an unparalleled “sense of mission”.

Genetics 106

Genetics Marketing Development Genome 106

Drug Discovery World

SEPTEMBER 7, 2022

The incredible speeds at which Covid-19 vaccines were successfully developed and brought to market highlighted to the world and the industry that lengthy development timelines aren’t always assured. The pandemic also highlighted the need for life sciences companies to adopt technologies that can help them work more efficiently.

Research 52

Research Scientist Clinical Trials Clinical Trials 52